US · Healthcare · Biotechnology
EPS came in at -1.08 against a street estimate of -0.35 — a miss of 208.6%.
Analysts rate Mirum Pharmaceuticals Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $146.50.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 12.59% |
| HHG PLC | 11.39% |
| BlackRock Inc | 6.31% |
| Vanguard Capital Management, LLC | 3.96% |
| FMR Inc | 3.22% |
| State Street Corp | 3.19% |
| T. Rowe Price Associates, Inc. | 2.82% |
| Bvf Inc | 2.60% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-18 |
| Material agreement · Q2 2026 | 2026-05-18 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Company announcement · Q2 2026 | 2026-05-04 |
| Proxy statement · Q4 2025 | 2026-04-23 |
| Annual report FY2025 | 2026-02-25 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Mirum Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.